Shares of Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.22. Hemispherx BioPharma shares last traded at $0.22, with a volume of 303,688 shares trading hands.
Hemispherx BioPharma Trading Up 2.8 %
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Further Reading
- Five stocks we like better than Hemispherx BioPharma
- What is a Secondary Public Offering? What Investors Need to Know
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Stock Dividend Cuts Happen Are You Ready?
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
